Viyash Scientific

Viyash Scientific FCF Yield

The Free Cash Flow Yield of Viyash Scientific (VIYASH.NS) as of Nov 4, 2026 is 0.47 %. In the previous year, Free Cash Flow Yield was -0.06 % — a change of -954.50% (higher).

FCF Yield

0.47 %

YoY

-954.50%

Last updated:

Free Cash Flow Yield of Viyash Scientific is 2025 0.47 % . Free Cash Flow Yield of Viyash Scientific was 2024 -0.06 % . It decreases by -954.50% higher compared to the previous year.

The Viyash Scientific FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2018
-0.02 INR
Jan 1, 2019
1.00 INR
Jan 1, 2020
0.82 INR
Jan 1, 2021
0.68 INR
Jan 1, 2022
-0.00 INR
Jan 1, 2023
-0.77 INR
Jan 1, 2024
-0.06 INR
Jan 1, 2025
0.47 INR
The Viyash Scientific FCF Yield history
YEARFCF YieldYoY
0.47 %-954.50%
-0.06 %-92.76%
-0.77 %+17,242.75%
-0.00-100.65%
0.68 %-17.01%
0.82 %-17.62%
1.00 %-5,188.20%
-0.02 %-97.93%
-0.95 %+31.01%
-0.72 %-42.71%
-1.26 %-12.22%
-1.44 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Viyash Scientific Stock analysis

What does Viyash Scientific do? Viyash Scientific Ltd generates revenue through the manufacturing and sale of veterinary pharmaceuticals and specialty chemicals. The company offers finished dose formulations, active pharmaceutical ingredients (APIs), and analytical services to clients in the pharmaceutical, personal care, and nutraceutical industries. Its products target therapies such as anthelmintics, anti-protozoals, nutraceuticals, NSAIDs, anti-infectives, and dermatology solutions. The firm operates primarily through its pharmaceuticals segment, with subsidiaries Alivira Animal Health Limited and SeQuent Research Limited supporting its analytical and bioanalytical service offerings. The company's analytical services include method validation, stability testing, microbiology, and in-house method development, adhering to pharmacopoeia monographs and customer-specific requirements. These services are provided to API, pharmaceutical, personal care, and nutraceutical companies seeking regulatory compliance and quality assurance. The firm's focus on targeted therapies and specialized services positions it to serve a niche market within the animal health sector. Viyash Scientific Ltd's revenue streams are derived from both product sales and service contracts. The pharmaceuticals segment, which includes APIs and finished formulations, represents a core business area, while analytical services form a complementary revenue source. The company leverages its subsidiaries to enhance its service capabilities, particularly in analytical and bioanalytical support for clients across multiple industries. Viyash Scientific is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Viyash Scientific stock

Free Cash Flow Yield of Viyash Scientific is 0.47 % in 2025.

Free Cash Flow Yield of Viyash Scientific changed from -0.06 % to 0.47 %, representing a -954.50% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Viyash Scientific since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Viyash Scientific with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Viyash Scientific

All Key Metrics — Viyash Scientific